FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention relates to industrial technology of ready-made medicinal agents and discloses pharmaceutical compositions based on dimethyl fumarate. Dosage form is capsule containing 1 or more tablets coated with an enteric coating. Dimethyl fumarate content makes 20–42 % of tablet core weight.
EFFECT: invention allows simplifying the technology of manufacturing and dispensing the ready dosage form.
21 cl, 8 tbl, 4 ex, 2 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| APPLICATION OF FUMARIC ACID DERIVATIVES | 1998 |
|
RU2197963C2 |
| FUMARIC ACID-BASE MICROTABLETS | 1999 |
|
RU2210366C2 |
| APPLICATION OF DERIVATIVES OF FUMARIC ACID IN TRANSPLANTATION MEDICINE | 1999 |
|
RU2210364C2 |
| DIMETHYL FUMARATE-CONTAINING ENTERIC TABLET | 2020 |
|
RU2786364C1 |
| DERIVATIVES OF FUMARIC ACID AS NF-kappaB INHIBITOR | 2002 |
|
RU2282440C2 |
| PHARMACEUTICAL COMPOSITION COMPRISING MELATONIN AND DIPHENHYDRAMINE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, DOSAGE FORM BASED ON PHARMACEUTICAL COMPOSITION COMPRISING MELATONIN AND DIPHENHYDRAMINE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, METHOD FOR PREPARING AND USING DOSAGE FORM BASED ON PHARMACEUTICAL COMPOSITION CONTAINING MELATONIN AND DIPHENHYDRAMINE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | 2021 |
|
RU2818092C1 |
| USING FUMARIC ACID DERIVATIVES FOR TREATING CARDIAC FAILURE, MYOCARDIAL INFARCTION AND ANGINA | 2007 |
|
RU2459621C2 |
| PHARMACEUTICAL COMPOSITION POSSESSING THERAPEUTIC EFFECT ON DEMYELINATING DISEASES (VERSIONS) | 2015 |
|
RU2611415C1 |
| PHARMACEUTICAL COMPOSITION CONTAINING ROSUVASTATIN CALCIUM SALT (VERSIONS) | 2015 |
|
RU2606592C1 |
| USING DERIVATIVES OF FUMARIC ACID IN TREATMENT OF CARDIAC INSUFFICIENCY AND ASTHMA | 2004 |
|
RU2313339C2 |
